Official Corporate & Pipeline Release Privately Held · Sheridan, Wyoming

Xycota Biosciences Advances Preclinical Sub-Perceptual Neuroplasticity Pipeline Across Mild PTSD (XYCO-02) and Frontotemporal Dementia (XYCO-01)

Independent, privately held CNS biotechnology company prepares Health Canada Clinical Trial Application with CRO partner KGK Science for outpatient psilocybin capsule XYCO-02 while advancing Colorado exosome psilocin formulation program

· Issuer: Xycota Biosciences, LLC (Privately Held) · Stage: Preclinical & Investigational

SHERIDAN, Wyo., November 20, 2026. Xycota Biosciences, LLC (https://xycota.com), an independent, privately held central-nervous-system (CNS) biotechnology company developing standardized, non-hallucinogenic neuroplasticity candidates targeting the BDNF/TrkB pathway, today provided a scientific and operational update across its preclinical pipeline: lead outpatient candidate XYCO-02 for mild post-traumatic stress disorder (PTSD) and follow-on orphan neurology candidate XYCO-01 for frontotemporal dementia (FTD).

First-generation psychedelic clinical programs have established broad human safety pharmacology for psilocybin while highlighting two practical hurdles for scalable psychiatric and neurological care: 6-to-8-hour supervised in-clinic dosing sessions and functional unblinding exceeding 90 percent in published high-dose trials. Xycota Biosciences was founded to test a narrower, falsifiable translational question: whether a standardized, sub-perceptual psilocybin or psilocin regimen can engage neurotrophic synaptic signaling in humans without inducing an acute hallucinogenic experience or requiring full-day clinic stays.

Key Preclinical Pipeline & Operational Highlights

“Working adults, veterans, first responders, and neurology families need rigorous drug development engineered around real-world outpatient life rather than full-day specialty clinic stays,” said Brad Listermann, Co-Founder and Chief Executive Officer of Xycota Biosciences. “As an independent, privately held biotech company, our focus is disciplined execution: completing our Health Canada CTA package with KGK Science for XYCO-02 and advancing our Colorado exosome formulation work for XYCO-01.”

“The 2026 rat receptor-blockade data gave us a clear mechanistic hypothesis to test,” said Marvin S. Hausman, MD, Co-Founder and Chief Scientific Officer of Xycota Biosciences, immunologist, former U.S. Public Health Service surgeon at the National Institutes of Health, and architect of six FDA-approved New Drug Applications. “Animal pharmacology never substitutes for human clinical data. Our proposed 28-day double-blind trial in mild PTSD is designed to test directly whether a sub-perceptual oral capsule produces a measurable clinical signal while preserving trial blinding.”

About Xycota Biosciences, LLC

Xycota Biosciences, LLC (https://xycota.com), headquartered in Sheridan, Wyoming, is an independent, privately held central-nervous-system (CNS) biotechnology company advancing preclinical candidates targeting BDNF/TrkB synaptic signaling. Lead investigational candidate XYCO-02 is a standardized sub-perceptual oral psilocybin capsule in Health Canada Clinical Trial Application preparation for mild PTSD. Follow-on investigational candidate XYCO-01 is an engineered exosome-encapsulated psilocin formulation for frontotemporal dementia (FDA Orphan Drug Designation request filed, not granted). Xycota is led by Co-Founders Brad Listermann (CEO) and Marvin S. Hausman, MD (CSO), Senior Lab Operations Manager Anthony Smith, PhD, and Board Director Lt. Col. Elton L. Johnson Jr., U.S. Army (Ret.). Xycota Biosciences, LLC has no public stock ticker, is not traded on any stock exchange or over-the-counter market, and is not party to any pending merger or acquisition transaction; any earlier third-party announcements referencing a proposed acquisition of Xycota are no longer in effect.

Investigational Status & Forward-Looking Statements Notice

All Xycota Biosciences candidates (XYCO-01 and XYCO-02) are preclinical and investigational, involve controlled substances handled exclusively through DEA- and Health Canada-licensed contract partners, and have not been approved by the U.S. Food and Drug Administration (FDA), Health Canada, or any regulatory authority. Neither candidate has been evaluated in a company-sponsored human clinical study, no clinical trial has been authorized or opened for recruitment, and no claims of human clinical safety or therapeutic efficacy are made. Filing an FDA Orphan Drug Designation request is an application step and does not guarantee designation or regulatory approval. Statements regarding proposed clinical trial applications, study designs, formulation programs, and development timelines are forward-looking and subject to scientific, regulatory, manufacturing, and financing risks that may cause actual outcomes to differ materially. Nothing in this release constitutes medical advice, investment advice, an offer to sell, or a solicitation of an offer to buy any security.

Media, Institutional Investor & Partnering Contact: Brad Listermann, Co-Founder & CEO | investors@xycota.com | brad@xycota.com | https://xycota.com/investors

Institutional Investors & Licensing Teams Watch the 3-minute Investor Briefing or request NDA-gated Data Room access.